Literature DB >> 31933283

Recent Advances in the Treatment of Huntington's Disease: Targeting DNA and RNA.

Kathleen M Shannon1.   

Abstract

Huntington's disease is a dominantly inherited neurodegenerative disease caused by an unstable expanded trinucleotide repeat at the short end of the fourth chromosome. Central nervous system pathology begins in the striatum, eventually affecting the entire brain and occurs consequent to multiple intracellular derangements. The proximate cause is a mutant protein with an elongated polyglutamine tract. Pharmacological approaches targeting multiple domains of intracellular functions have universally been disappointing. However, recent developments in gene therapy, including antisense oligonucleotides, small interfering RNAs, and gene editing are bringing new hope to the Huntington's community. This review discusses the promises and challenges of these new potential treatments.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31933283     DOI: 10.1007/s40263-019-00695-3

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  91 in total

1.  Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo.

Authors:  Ryan L Boudreau; Inês Martins; Beverly L Davidson
Journal:  Mol Ther       Date:  2008-11-11       Impact factor: 11.454

2.  Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice.

Authors:  Mireia Garriga-Canut; Carmen Agustín-Pavón; Frank Herrmann; Aurora Sánchez; Mara Dierssen; Cristina Fillat; Mark Isalan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-10       Impact factor: 11.205

3.  Wild-type huntingtin participates in protein trafficking between the Golgi and the extracellular space.

Authors:  Anne N T Strehlow; Jun Z Li; Richard M Myers
Journal:  Hum Mol Genet       Date:  2006-12-22       Impact factor: 6.150

4.  Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.

Authors:  Laura Rué; Mónica Bañez-Coronel; Jordi Creus-Muncunill; Albert Giralt; Rafael Alcalá-Vida; Gartze Mentxaka; Birgit Kagerbauer; M Teresa Zomeño-Abellán; Zeus Aranda; Veronica Venturi; Esther Pérez-Navarro; Xavier Estivill; Eulàlia Martí
Journal:  J Clin Invest       Date:  2016-10-10       Impact factor: 14.808

5.  Region-specific pro-survival signaling and global neuronal protection by wild-type Huntingtin.

Authors:  Caodu Buren; Liang Wang; Amy Smith-Dijak; Lynn A Raymond
Journal:  J Huntingtons Dis       Date:  2014

6.  Neuroprotection in Huntington's disease: a 2-year study on minocycline.

Authors:  Raphael M Bonelli; Anna K Hödl; Peter Hofmann; Hans-Peter Kapfhammer
Journal:  Int Clin Psychopharmacol       Date:  2004-11       Impact factor: 1.659

7.  rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse.

Authors:  Yoko Machida; Takashi Okada; Masaru Kurosawa; Fumitaka Oyama; Keiya Ozawa; Nobuyuki Nukina
Journal:  Biochem Biophys Res Commun       Date:  2006-03-03       Impact factor: 3.575

Review 8.  Antisense oligonucleotides: the next frontier for treatment of neurological disorders.

Authors:  Carlo Rinaldi; Matthew J A Wood
Journal:  Nat Rev Neurol       Date:  2017-12-01       Impact factor: 42.937

9.  An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.

Authors:  Sigurd D Süssmuth; Salman Haider; G Bernhard Landwehrmeyer; Ruth Farmer; Chris Frost; Giovanna Tripepi; Claus A Andersen; Marco Di Bacco; Claudia Lamanna; Enrica Diodato; Luisa Massai; Daniela Diamanti; Elisa Mori; Letizia Magnoni; Jens Dreyhaupt; Karin Schiefele; David Craufurd; Carsten Saft; Monika Rudzinska; Danuta Ryglewicz; Michael Orth; Sebastian Brzozy; Anna Baran; Giuseppe Pollio; Ralph Andre; Sarah J Tabrizi; Borje Darpo; Goran Westerberg
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 10.  Normal huntingtin function: an alternative approach to Huntington's disease.

Authors:  Elena Cattaneo; Chiara Zuccato; Marzia Tartari
Journal:  Nat Rev Neurosci       Date:  2005-12       Impact factor: 34.870

View more
  7 in total

Review 1.  Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.

Authors:  Dharmendra Kumar Khatri; Amey Kadbhane; Monica Patel; Shweta Nene; Srividya Atmakuri; Saurabh Srivastava; Shashi Bala Singh
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-04-08

2.  Fighting the Huntington's Disease with a G-Quadruplex-Forming Aptamer Specifically Binding to Mutant Huntingtin Protein: Biophysical Characterization, In Vitro and In Vivo Studies.

Authors:  Claudia Riccardi; Federica D'Aria; Filomena Anna Digilio; Maria Rosaria Carillo; Jussara Amato; Dominga Fasano; Laura De Rosa; Simona Paladino; Mariarosa Anna Beatrice Melone; Daniela Montesarchio; Concetta Giancola
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

3.  Divergent Effects of the Nonselective Adenosine Receptor Antagonist Caffeine in Pre-Manifest and Motor-Manifest Huntington's Disease.

Authors:  Jannis Achenbach; Andreas Matusch; David Elmenhorst; Andreas Bauer; Carsten Saft
Journal:  Biomedicines       Date:  2022-05-27

Review 4.  Molecular Mechanisms Underlying Muscle Wasting in Huntington's Disease.

Authors:  Manuela Bozzi; Francesca Sciandra
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

5.  Deep-learning analysis of micropattern-based organoids enables high-throughput drug screening of Huntington's disease models.

Authors:  Jakob J Metzger; Carlota Pereda; Arjun Adhikari; Tomomi Haremaki; Szilvia Galgoczi; Eric D Siggia; Ali H Brivanlou; Fred Etoc
Journal:  Cell Rep Methods       Date:  2022-09-19

6.  Drumming Motor Sequence Training Induces Apparent Myelin Remodelling in Huntington's Disease: A Longitudinal Diffusion MRI and Quantitative Magnetization Transfer Study.

Authors:  Chiara Casella; Jose Bourbon-Teles; Sonya Bells; Elizabeth Coulthard; Greg D Parker; Anne Rosser; Derek K Jones; Claudia Metzler-Baddeley
Journal:  J Huntingtons Dis       Date:  2020

Review 7.  Insights into Human-Induced Pluripotent Stem Cell-Derived Astrocytes in Neurodegenerative Disorders.

Authors:  Mandeep Kumar; Nhung Thi Phuong Nguyen; Marco Milanese; Giambattista Bonanno
Journal:  Biomolecules       Date:  2022-02-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.